Straumann Holding AG/Fr. STMN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Straumann Holding AG
Straumann Holding AG operates in the healthcare sector, focusing on dental and orthodontic solutions. The company specializes in developing and manufacturing dental implants, clear aligners, and digital solutions for dentists and orthodontists. Founded in 1954 and headquartered in Basel, Switzerland, Straumann has expanded its geographic footprint globally with operations in Europe, North America, Latin America, and Asia Pacific. The company's strategic positioning is supported by its strong focus on research and development, which contributes to its innovative product offerings and comprehensive digital dentistry solutions. Straumann's competitive strengths include its robust product portfolio and extensive network of professional training and support services for dental practitioners.
- Ticker
- Fr. STMN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 11,582
- Headquarters
- Basel, Switzerland
- Website
- www.straumann.com
STMN Metrics
BasicAdvanced
CHF 16B
42.23
CHF 2.31
1.38
CHF 1.00
1.03%
Price and volume
Market cap
CHF 16B
Beta
1.38
52-week high
CHF 109.80
52-week low
CHF 73.02
Average daily volume
394K
Dividend rate
CHF 1.00
Financial strength
Current ratio
2.264
Quick ratio
1.607
Long term debt to equity
0.208
Total debt to equity
0.208
Dividend payout ratio (TTM)
42.96%
Interest coverage (TTM)
20.72%
Profitability
EBITDA (TTM)
750.603
Gross margin (TTM)
69.26%
Net profit margin (TTM)
14.00%
Operating margin (TTM)
24.70%
Effective tax rate (TTM)
22.14%
Revenue per employee (TTM)
CHF 230,000
Management effectiveness
Return on assets (TTM)
10.99%
Return on equity (TTM)
17.05%
Valuation
Price to earnings (TTM)
42.23
Price to revenue (TTM)
5.891
Price to book
6.79
Price to tangible book (TTM)
11.05
Price to free cash flow (TTM)
45.861
Free cash flow yield (TTM)
2.18%
Free cash flow per share (TTM)
2.127
Dividend yield (TTM)
1.03%
Forward dividend yield
1.03%
Growth
Revenue change (TTM)
2.24%
Earnings per share change (TTM)
-6.64%
3-year revenue growth (CAGR)
4.87%
10-year revenue growth (CAGR)
11.84%
3-year earnings per share growth (CAGR)
-0.56%
10-year earnings per share growth (CAGR)
6.10%
3-year dividend per share growth (CAGR)
7.72%
10-year dividend per share growth (CAGR)
9.60%
Bulls say / Bears say
Organic growth accelerated to 8.5% in the second quarter, and first-half sales reached CHF 1.38 billion. Straumann maintained its full-year target of high-single-digit organic growth, signalling continued demand across its business. (Reuters)
Management raised its 2026 core EBIT margin expansion target to 140–170 basis points from 30–60 basis points, citing stronger execution, manufacturing efficiencies and lower-than-expected tariffs. This points to improving profitability alongside revenue growth. (EQS News)
Strong scanner sales and broader use of the AXS digital platform, alongside iEXCEL-driven customer wins and market-share gains, support Straumann’s growth beyond implants alone. These connected tools could deepen customer engagement and create further sales opportunities across its product range. (EQS News)
China remains a drag: sales there were sluggish as dentists and distributors awaited clarity on the next government volume-based procurement round. Straumann said the process could start in late 2026, with implementation planned for early 2027, leaving pricing and demand uncertain in the meantime. (Dental Tribune)
Deutsche Bank warned that the shares’ premium valuation leaves little room for weaker growth, citing about 26 times projected 2027 earnings. A slowdown could therefore prompt a sharp share-price reassessment even if the longer-term business outlook remains positive. (Investing.com)
CEO Guillaume Daniellot is due to leave at year-end, creating a leadership handover just as Straumann pursues a new medium-term strategy. Investors may worry that a change at the top could disrupt execution or increase uncertainty around the company’s plans. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2026.
Upcoming events
No upcoming events
Funds containing STMN
AllEURUSDGBP
Fund name | Fund size | Fr. STMN weighting |
|---|---|---|
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 0.69% |
iShares MSCI Europe Health Care Sector€ESIH | €890M | 0.68% |
iShares MSCI Europe Health Care Sector£ESIH | €890M | 0.68% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 0.59% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 0.59% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.